Ref.: BL-RE-093621Manufacturer ref.: EH197RBX10 10 x 96 tests
€4,995.00 excl. VAT
Human Flt-3 quantitates human Flt-3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Flt-3.
Accession number
B230315G04 ; CD135 ; antigène CD135 ; kinase 2 du foie fœtal ; kinase-2 du foie fœtal ; récepteur de cytokine FL ; Flk2 ; Flk-2 ; FLT3 ; Flt-3 ; tyrosine kinase 3 associée au FMS ; tyrosine kinase 3 similaire au FMS ; tyrosine kinase 3 liée au FMS ; tyrosine kinase du récepteur des facteurs de croissance type III ; Ly72 ; OTTHUMP00000214829 ; tyrosine-protéine kinase de type récepteur FLT3 ; RP11-153M24.3 ; tyrosine kinase de la cellule souche 1 ; STK1 ; protéine-kinase FLK3 ; protéine FLtyrosine ; protéine FLT3 associée à la tyrosine
Dose range
0.246 to 60 ng/ml
Sensitivity of the dosage
0.24 ng/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen
Human Flt-3 quantitates human Flt-3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Flt-3.
Human Flt-3 quantitates human Flt-3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Flt-3.
This gene codes a tyrosine kinase of the Class III receptor that regulates the haematopoiesis. The receptor consists of an extracellular domain consisting of five domains similar to l-immunoglobulin, a transmembrane zone and a cytoplasmic kinase domain divided into two parts by a field of kinase insertion. The receptor is activated by binding of tyrosine kinase 3 ligand associated with FMS to the extracellular domain, which induces the formation of homodomer in the plasma membrane leading to the receptor selfphosphorylation. The kinase of the phosphoryl activated receptors subsequently activates several cytoplasmic effecting molecules in the pathways involved in the apoptosis, proliferation and differentiation of haematopoietic cells in the bone marrow. Mutations that cause the constitutive activation of this receptor result in acute myeloid leukaemia and acute lymphoblastic leukaemia.
Sensitivity
Sensitivity of the dosage: 0.24 ng/ml.
Measurement range
Dose range: 0.246 to 60 ng/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Target
Target: FLT3 (CD135).
Technical specifications
General
Brand
Invitrogen
Supplier ref. (Fisher Scientific)
17864090
Specifications
Accession number
B230315G04; CD135; CD135 antigen; foetal liver kinase 2; foetal liver kinase-2; cytokine FL receptor; Flk2; Flk-2; FLT3; Flt-3; tyrosine kinase 3 associated with FMS; tyrosine kinase 3 similar to FMS; tyrosine kinase 3 related to FMS; tyrosine kinase of the crousal factor receptor